» Articles » PMID: 15046220

Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis

Overview
Specialty Gastroenterology
Date 2004 Mar 30
PMID 15046220
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Nonalcoholic steatohepatitis (NASH) associated with obesity and type 2 diabetes mellitus (DM) is postulated to be the cause of most cases of cryptogenic cirrhosis (CC). While ethnic differences in the prevalence of obesity and DM in the United States are well documented, there is little information regarding prevalence of CC or NASH among different U.S. ethnic groups. This study was performed to assess the demographic characteristics of patients with CC at a U.S. county hospital with a racially and ethnically diverse patient population.

Methods: Medical records and pathology databases were reviewed to identify patients at Parkland Memorial Hospital, Dallas County, Texas from 1990 to 2001 with CC or cirrhosis attributed to NASH.

Results: Forty-one patients (12 men, 29 women) were found to meet these criteria. Of these, 68% were obese (BMI > or = 30) and/or had type 2 DM and 74% of liver biopsies revealed one or more features of NASH. Of patients with CC 68% were Hispanic while only 7% were African American, despite the fact that Hispanics comprised < 26% and African Americans > 40% of adult medicine patients. Prevalence of CC among Hispanic and African American patients was 3.1-fold higher and 3.9-fold lower, respectively, than among European American patients despite similar prevalence of DM among Hispanics and African Americans.

Conclusion: These findings support the hypothesis that NASH associated with obesity and DM is responsible for the majority of cases of CC among Hispanics and European Americans. However, the current findings also indicate that this form of cirrhosis is unexpectedly rare among African Americans.

Citing Articles

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease.

Kozlitina J, Sookoian S Liver Int. 2024; 45(3):e16123.

PMID: 39373119 PMC: 11815610. DOI: 10.1111/liv.16123.


Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy.

Habib S World J Gastrointest Pathophysiol. 2024; 15(4):93606.

PMID: 39220834 PMC: 11362842. DOI: 10.4291/wjgp.v15.i4.93606.


Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function.

Villarroel C, Karim G, Sehmbhi M, Debroff J, Weisberg I, Dinani A Gastro Hep Adv. 2024; 3(1):122-127.

PMID: 39132183 PMC: 11307954. DOI: 10.1016/j.gastha.2023.09.008.


Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes.

Yen Y, Kuo F, Eng H, Liu Y, Yong C, Wang C Updates Surg. 2024; 76(3):879-887.

PMID: 38582796 DOI: 10.1007/s13304-024-01833-3.


Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review.

Ghazanfar H, Javed N, Qasim A, Sarin Zacharia G, Ghazanfar A, Jyala A Cancers (Basel). 2024; 16(6).

PMID: 38539547 PMC: 10969013. DOI: 10.3390/cancers16061214.